UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 1.442

Sortiert nach

Targeting the androgen receptor pathway in castration-resistant prostate cancer: progresses and prospects

Oncogene, 2015-04, Vol.34 (14), p.1745-1757

2015

Link zum Volltext

Verfügbarkeit prüfen

Duplication of the fusion of TMPRSS2 to ERG sequences identifies fatal human prostate cancer

Oncogene, 2008-01, Vol.27 (3), p.253-263

2008

Link zum Volltext

Verfügbarkeit prüfen

Translating cancer research into targeted therapeutics

Nature (London), 2010-09, Vol.467 (7315), p.543-549

2010

Link zum Volltext

Verfügbarkeit prüfen

Phase II, two-stage, single-arm trial of the histone deacetylase inhibitor (HDACi) romidepsin in metastatic castration-resistant prostate cancer (CRPC)

Annals of oncology, 2010-01, Vol.21 (1), p.109-113

2010

Link zum Volltext

Verfügbarkeit prüfen

Characterization of the adaptive and innate immune response to intravenous oncolytic reovirus (Dearing type 3) during a phase I clinical trial

Gene therapy, 2008-06, Vol.15 (12), p.911-920

2008

Link zum Volltext

Verfügbarkeit prüfen

Molecularly targeted therapies in cancer: a guide for the nuclear medicine physician

European journal of nuclear medicine and molecular imaging, 2017-08, Vol.44 (Suppl 1), p.41-54

2017

Link zum Volltext

Verfügbarkeit prüfen

Antitumour activity of abiraterone acetate against metastatic castration-resistant prostate cancer progressing after docetaxel and enzalutamide (MDV3100)

Annals of oncology, 2013-07, Vol.24 (7), p.1807-1812

2013

Link zum Volltext

Verfügbarkeit prüfen

Antitumour activity of enzalutamide (MDV3100) in patients with metastatic castration-resistant prostate cancer (CRPC) pre-treated with docetaxel and abiraterone

European journal of cancer (1990), 2014-01, Vol.50 (1), p.78-84

2014

Link zum Volltext

Verfügbarkeit prüfen

Analysis of DNA methylation in single circulating tumor cells

Oncogene, 2017-06, Vol.36 (23), p.3223-3231

2017

Link zum Volltext

Verfügbarkeit prüfen

Circulating tumour cell (CTC) counts as intermediate end points in castration-resistant prostate cancer (CRPC): a single-centre experience

Annals of oncology, 2009-01, Vol.20 (1), p.27-33

2009

Link zum Volltext

Verfügbarkeit prüfen

Impact of cabazitaxel on 2-year survival and palliation of tumour-related pain in men with metastatic castration-resistant prostate cancer treated in the TROPIC trial

Annals of oncology, 2013-09, Vol.24 (9), p.2402-2408

2013

Link zum Volltext

Verfügbarkeit prüfen

Application of Liquid Biopsies in Cancer Targeted Therapy

Clinical pharmacology and therapeutics, 2017-11, Vol.102 (5), p.745-747

2017

Link zum Volltext

Verfügbarkeit prüfen

What is the impact of targeted therapies given within phase I trials on the cognitive function of patients with advanced cancer: a mixed-methods exploratory study conducted in an early clinical trials unit

BMJ open, 2022-11, Vol.12 (11), p.e050590

2022

Link zum Volltext

Verfügbarkeit prüfen

Molecular alterations and emerging targets in castration resistant prostate cancer

European journal of cancer (1990), 2014-03, Vol.50 (4), p.753-764

2014

Link zum Volltext

Verfügbarkeit prüfen

Randomised phase II study of siltuximab (CNTO 328), an anti-IL-6 monoclonal antibody, in combination with mitoxantrone/prednisone versus mitoxantrone/prednisone alone in metastatic castration-resistant prostate cancer

European journal of cancer (1990), 2012-01, Vol.48 (1), p.85-93

2012

Link zum Volltext

Verfügbarkeit prüfen

Pharmacokinetic and pharmacodynamic properties of an oral formulation of the histone deacetylase inhibitor Belinostat (PXD101)

Cancer chemotherapy and pharmacology, 2011-06, Vol.67 (6), p.1273-1279

2011

Link zum Volltext

Verfügbarkeit prüfen

Improved outcomes in elderly patients with metastatic castration-resistant prostate cancer treated with the androgen receptor inhibitor enzalutamide: results from the phase III AFFIRM trial

Annals of oncology, 2014-02, Vol.25 (2), p.429-434

2014

Link zum Volltext

Verfügbarkeit prüfen

All circulating EpCAM+CK+CD45- objects predict overall survival in castration-resistant prostate cancer

Annals of oncology, 2010-09, Vol.21 (9), p.1851-1857

2010

Link zum Volltext

Verfügbarkeit prüfen

Exploratory analysis of the visceral disease subgroup in a phase III study of abiraterone acetate in metastatic castration-resistant prostate cancer

Prostate cancer and prostatic diseases, 2014-03, Vol.17 (1), p.34-39

2014

Link zum Volltext

Verfügbarkeit prüfen

Clinical variables associated with PSA response to abiraterone acetate in patients with metastatic castration-resistant prostate cancer

Annals of oncology, 2014-03, Vol.25 (3), p.657-662

2014

Link zum Volltext

Verfügbarkeit prüfen

A decade of clinical development of PARP inhibitors in perspective

Annals of oncology, 2019-09, Vol.30 (9), p.1437-1447

2019

Link zum Volltext

Verfügbarkeit prüfen

Association of creatine kinase and skin toxicity in phase I trials of anticancer agents

British journal of cancer, 2012-11, Vol.107 (11), p.1797-1800

2012

Link zum Volltext

Verfügbarkeit prüfen

Effect of abiraterone acetate on fatigue in patients with metastatic castration-resistant prostate cancer after docetaxel chemotherapy

Annals of oncology, 2013-04, Vol.24 (4), p.1017-1025

2013

Link zum Volltext

Verfügbarkeit prüfen

CYP17 blockade by abiraterone: further evidence for frequent continued hormone-dependence in castration-resistant prostate cancer

British journal of cancer, 2009-03, Vol.100 (5), p.671-675

2009

Link zum Volltext

Verfügbarkeit prüfen

Phase I and pharmacokinetic (PK) study of MAG-CPT (PNU 166148): a polymeric derivative of camptothecin (CPT)

British journal of cancer, 2004-07, Vol.91 (1), p.50-55

2004

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 1.442

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(1.286)
Mit Volltextzugriff
(1.353)

Publikationsform

5 weitere anzeigen...

Weniger anzeigen...

Sprache

5 weitere anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

Science & Technology
(613)
Life Sciences & Biomedicine
(555)
Humans
(539)
Male
(397)
Middle Aged
(258)
Oncology
(238)
Aged
(231)
Biological And Medical Sciences
(223)
Medical Sciences
(212)
Female
(209)
Adult
(163)
Tumors
(106)
Treatment Outcome
(102)
Prostate Cancer
(97)
Animals
(91)
Aged, 80 And Over
(86)
Pharmacology. Drug Treatments
(84)
General & Internal Medicine
(73)
Prostatic Neoplasms, Castration-Resistant - Drug Therapy
(73)
Antineoplastic Agents - Therapeutic Use
(68)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(2)
... seit 90 Tagen
(6)

Menü

Weitere Dienste

Einstellungen

Targeting the androgen receptor pathway in castration-resistant prostate cancer: progresses and prospects

Duplication of the fusion of TMPRSS2 to ERG sequences identifies fatal human prostate cancer

Translating cancer research into targeted therapeutics

Phase II, two-stage, single-arm trial of the histone deacetylase inhibitor (HDACi) romidepsin in metastatic castration-resistant prostate cancer (CRPC)

Characterization of the adaptive and innate immune response to intravenous oncolytic reovirus (Dearing type 3) during a phase I clinical trial

Molecularly targeted therapies in cancer: a guide for the nuclear medicine physician

Antitumour activity of abiraterone acetate against metastatic castration-resistant prostate cancer progressing after docetaxel and enzalutamide (MDV3100)

Antitumour activity of enzalutamide (MDV3100) in patients with metastatic castration-resistant prostate cancer (CRPC) pre-treated with docetaxel and abiraterone

Analysis of DNA methylation in single circulating tumor cells

Circulating tumour cell (CTC) counts as intermediate end points in castration-resistant prostate cancer (CRPC): a single-centre experience

Impact of cabazitaxel on 2-year survival and palliation of tumour-related pain in men with metastatic castration-resistant prostate cancer treated in the TROPIC trial

Application of Liquid Biopsies in Cancer Targeted Therapy

What is the impact of targeted therapies given within phase I trials on the cognitive function of patients with advanced cancer: a mixed-methods exploratory study conducted in an early clinical trials unit

Molecular alterations and emerging targets in castration resistant prostate cancer

Randomised phase II study of siltuximab (CNTO 328), an anti-IL-6 monoclonal antibody, in combination with mitoxantrone/prednisone versus mitoxantrone/prednisone alone in metastatic castration-resistant prostate cancer

Pharmacokinetic and pharmacodynamic properties of an oral formulation of the histone deacetylase inhibitor Belinostat (PXD101)

Improved outcomes in elderly patients with metastatic castration-resistant prostate cancer treated with the androgen receptor inhibitor enzalutamide: results from the phase III AFFIRM trial

All circulating EpCAM+CK+CD45- objects predict overall survival in castration-resistant prostate cancer

Exploratory analysis of the visceral disease subgroup in a phase III study of abiraterone acetate in metastatic castration-resistant prostate cancer

Clinical variables associated with PSA response to abiraterone acetate in patients with metastatic castration-resistant prostate cancer

A decade of clinical development of PARP inhibitors in perspective

Association of creatine kinase and skin toxicity in phase I trials of anticancer agents

Effect of abiraterone acetate on fatigue in patients with metastatic castration-resistant prostate cancer after docetaxel chemotherapy

CYP17 blockade by abiraterone: further evidence for frequent continued hormone-dependence in castration-resistant prostate cancer

Phase I and pharmacokinetic (PK) study of MAG-CPT (PNU 166148): a polymeric derivative of camptothecin (CPT)

Suchergebnisse filtern